.jpeg "Akums Strengthens PHN Treatment with Gabapentin ER Launch")
Akums launches an enhanced Gabapentin ER for postherpetic neuralgia, using sustained-release technology to improve pain control, once-daily dosing and patient adherence in India.
AstraZeneca and Daiichi Sankyo received FDA approval for Enhertu as a first?line therapy for HER2-positive metastatic breast cancer, altering treatment for newly diagnosed patients.The ruling will allow the use of Enhertu with Perjeta developed...
Biocon launches its GLP-1 drug Liraglutide in the Netherlands, entering Europe with branded diabetes and obesity therapies, strengthening its GLP-1 and biologics portfolio.
GSK Nucala has moved a step closer to European approval after the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended the drug for adults with uncontrolled COPD marked by raised blood eosinophils.
Piramal Pharma Solutions NPS has reached a strong 55 for FY2025, signaling high customer loyalty and trust across its global operations. Announced today, the result highlights the company’s growing reputation as a reliable global CDMO and...
Indoco Remedies Limited has received a key regulatory clearance from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients operations, strengthening its position in the global pharmaceutical supply chain...
.png "Lupin's LMS and PolyPeptide Form Alliance to Strengthen Peptide Supply")
Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin Limited, announced a major strategic alliance today with PolyPeptide Group AG, marking a significant move in the expanding peptide market. The long-term partnership aims to build...
Piramal Pharma drew attention today as the US FDA wrapped up a general Good Manufacturing Practices inspection at the company’s Lexington, Kentucky site. The review, held from December 3 to December 10, 2025, ended with a Form 483 containing...
Pfizer’s HER2-targeted therapy TUKYSA delivered a strong boost in first-line maintenance treatment for HER2-positive metastatic breast cancer, marking a major advance in today’s data from the Phase 3 HER2CLIMB-05 trial.
Roche has announced fresh momentum in clinical diagnostics with CE Mark approval for its new mass spectrometry reagent pack, a move that strengthens its position in mass spectrometry testing. The approval expands what is now the broadest IVD...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")